Central muscarinic activities of an M1-selective agonist: preferential effect on reversal of amnesia
- 1 January 1990
- journal article
- research article
- Published by Elsevier in Brain Research
- Vol. 507 (1) , 172-175
- https://doi.org/10.1016/0006-8993(90)90541-i
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): A new M1 agonist attenuates cognitive dysfunctions in AF64A-treated ratsNeuroscience Letters, 1989
- Blockade of spatial learning by the M1 muscarinic antagonist pirenzepinePsychopharmacology, 1987
- RS 86 in the treatment of alzheimer's disease: Cognitive and biological effectsBiological Psychiatry, 1987
- Muscarinic activity of McN-A-343 and its value in muscarinic receptor classificationBritish Journal of Pharmacology, 1987
- MUSCARINIC RECEPTOR SUBTYPES: A CRITIQUE OF THE CURRENT CLASSIFICATION AND A PROPOSAL FOR A WORKING NOMENCLATUREJournal of Autonomic Pharmacology, 1986
- Cholinergic function and intellectual decline in Alzheimer's diseaseNeuroscience, 1986
- Central administration of the muscarinic receptor subtype - selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouseJournal of Pharmacy and Pharmacology, 1983
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982
- Pirenzepine distinguishes between different subclasses of muscarinic receptorsNature, 1980
- Memory and cognitive function in manNeurology, 1977